Feasibility study for 2nd line combination chemotherapy of Nab-paclitaxel with Ramucirumab for inoperable advanced recurrent gastric cancer.
Not Applicable
- Conditions
- Inoperable advanced recurrent gastric cancer (2nd line chemotherapy).
- Registration Number
- JPRN-UMIN000022221
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. History of serious allergic drug reaction 2. Synchronous or metachronous malignancies other than carcinoma in situ or mucosal carcinoma 3. history of paclitaxel administration 4. serious complications (pulmonary fibrosis or interstitial pneumonitis, renal failure, liver failure, cerebrovascular accident, ulcer using blood infusion, uncontolable diabetes mellitus) 5. serious infection 6. Massive pericardial effusion, pleural effusion or ascites 7. massive bone metastases 8. brain metastasis including suspicious state 9. Pregnant or lactating female 10. severe disorder of electrocardiogram 11. serious mental disorder 12. Judged inappropriate by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the accomplishment rate of 3 cycle chemotherapies
- Secondary Outcome Measures
Name Time Method Occurence frequency and degree of adverse event Disease Control Rate: DCR Response rate: RR Overall survival: OS